Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy comprising adaptive memory NK cells; FT500, an induced pluripotent stem cell (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516, an iPSC-derived non-cleavable CD16 engineered NK cell product candidate to treat hematologic malignancies and solid tumors; and FT596, a chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies. The company's immuno-oncology product candidates also include FT538, an NK cell product candidate for treating multiple myeloma; and FT819, a CAR T-cell product candidate for the treatment of liquid and solid tumors. Its immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and FT301, an immuno-regulatory cell product candidate for various disease indications, including graft-versus-host disease, multiple sclerosis, ulcerative colitis, and others. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; and strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone858-875-1800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.74 million
Profitability
Miscellaneous
Employees104
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable
Fate Therapeutics (NASDAQ:FATE) Frequently Asked Questions
What is Fate Therapeutics' stock symbol?
Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."
How were Fate Therapeutics' earnings last quarter?
Fate Therapeutics Inc (NASDAQ:FATE) announced its quarterly earnings results on Tuesday, March, 5th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by $0.01. Fate Therapeutics had a negative return on equity of 59.04% and a negative net margin of 1,405.06%. View Fate Therapeutics' Earnings History.
When is Fate Therapeutics' next earnings date?
What price target have analysts set for FATE?
8 brokerages have issued 12-month price objectives for Fate Therapeutics' stock. Their predictions range from $12.00 to $24.00. On average, they expect Fate Therapeutics' stock price to reach $19.6250 in the next twelve months. This suggests a possible upside of 20.9% from the stock's current price. View Analyst Price Targets for Fate Therapeutics.
What is the consensus analysts' recommendation for Fate Therapeutics?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fate Therapeutics.
What are Wall Street analysts saying about Fate Therapeutics stock?
Here are some recent quotes from research analysts about Fate Therapeutics stock:
- 1. According to Zacks Investment Research, "Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California. " (2/13/2019)
- 2. HC Wainwright analysts commented, "Our $12 price target is based on a sum-of-the-parts analysis based on probability-adjusted revenue forecasts for ProTmune and FATE-NK100. We use the net present value of our revenue forecast through 2026, apply a 40% probability of success for 2Q18 fully diluted net cash estimate of $0.84/share to arrive at our $12 price target. We value the early stage pipeline and Juno collaboration at $2.32/share. We assume a 25% discount rate for the NPV of the pipeline and a P/S multiple of 4x." (8/7/2018)
Has Fate Therapeutics been receiving favorable news coverage?
News articles about FATE stock have trended negative recently, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Fate Therapeutics earned a media sentiment score of -2.3 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the company's share price in the immediate future.
Who are some of Fate Therapeutics' key competitors?
Some companies that are related to Fate Therapeutics include China Biologic Products (CBPO), argenx (ARGX), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Repligen (RGEN), Denali Therapeutics (DNLI), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Regenxbio (RGNX), Crispr Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Audentes Therapeutics (BOLD), Orchard Therapeutics (ORTX), Alector (ALEC) and Atara Biotherapeutics (ATRA).
What other stocks do shareholders of Fate Therapeutics own?
Who are Fate Therapeutics' key executives?
Fate Therapeutics' management team includes the folowing people:
- Mr. J. Scott Wolchko, Founder, CEO, CFO, Pres, Treasurer, Sec. & Director (Age 49)
- Dr. Daniel D. Shoemaker, Chief Scientific Officer (Age 51)
- Ms. Cindy R. Tahl, Gen. Counsel & Compliance Officer (Age 46)
- Dr. Bahram Valamehr Ph.D., Chief Devel. Officer (Age 42)
- Dr. Wen Bo Wang, Sr. VP of Technical Operations
Who are Fate Therapeutics' major shareholders?
Fate Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Columbus Circle Investors (0.16%) and Meeder Asset Management Inc. (0.00%). Company insiders that own Fate Therapeutics stock include Amir Nashat, Cindy Tahl, Daniel D Shoemaker, J Scott Wolchko and Redmile Group, Llc. View Institutional Ownership Trends for Fate Therapeutics.
Which institutional investors are selling Fate Therapeutics stock?
FATE stock was sold by a variety of institutional investors in the last quarter, including Columbus Circle Investors. Company insiders that have sold Fate Therapeutics company stock in the last year include Amir Nashat, Cindy Tahl, Daniel D Shoemaker and J Scott Wolchko. View Insider Buying and Selling for Fate Therapeutics.
Which institutional investors are buying Fate Therapeutics stock?
How do I buy shares of Fate Therapeutics?
Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Fate Therapeutics' stock price today?
One share of FATE stock can currently be purchased for approximately $16.23.
How big of a company is Fate Therapeutics?
Fate Therapeutics has a market capitalization of $1.06 billion and generates $4.74 million in revenue each year. The biopharmaceutical company earns $-66,600,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Fate Therapeutics employs 104 workers across the globe.
What is Fate Therapeutics' official website?
How can I contact Fate Therapeutics?
Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected]
MarketBeat Community Rating for Fate Therapeutics (NASDAQ FATE)
MarketBeat's community ratings are surveys of what our community members think about Fate Therapeutics and other stocks. Vote "Outperform" if you believe FATE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FATE will underperform the S&P 500 over the long term. You may vote once every thirty days.
